We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+10.35%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$113M
AUM Growth
-$2.14M
(-1.9%)
Cap. Flow
-$5.51M
Cap. Flow
% of AUM
-4.87%
Top 10 Holdings %
Top 10 Hldgs %
14.17%
Holding
280
New
34
Increased
61
Reduced
100
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity MSCI Financials Index ETF
FNCL
|
+$1.46M |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.13M |
| 3 |
MediciNova
MNOV
|
+$969K |
| 4 |
ADVM
Adverum Biotechnologies
ADVM
|
+$866K |
| 5 |
CLSD
Clearside Biomedical
CLSD
|
+$856K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity MSCI Information Technology Index ETF
FTEC
|
+$2.78M |
| 2 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
+$1.32M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
+$1.22M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$1.01M |
| 5 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$938K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.9% |
| 2 | Financials | 0.8% |
| 3 | Technology | 0.58% |
| 4 | Consumer Discretionary | 0.4% |
| 5 | Energy | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SAGE
51
DELISTED
Sage Therapeutics
SAGE
| $771K | 0.68% |
4,923
+152
| +3% | +$23.9K |
|
|
TSRO
52
DELISTED
TESARO, Inc.
TSRO
| $770K | 0.68% |
17,317
+5,926
| +52% | +$288K |
|
|
ACHN
53
DELISTED
Achillion Pharmaceuticals
ACHN
| $768K | 0.68% |
271,426
+9,142
| +3% | +$31.1K |
|
|
SGYP
54
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $768K | 0.68% |
+441,461
| New | +$763K |
|
55
BioMarin Pharmaceuticals
BMRN
$11.5B
| $764K | 0.68% |
8,114
-2,197
| -21% | -$192K |
|
|
ESPR
56
DELISTED
Esperion Therapeutics
ESPR
| $764K | 0.68% |
19,484
+6,541
| +51% | +$330K |
|
57
Karyopharm Therapeutics
KPTI
$168M
| $764K | 0.68% |
2,999
-2,423
| -45% | -$599K |
|
|
ECYT
58
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $764K | 0.68% |
+55,345
| New | +$657K |
|
|
LJPC
59
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $764K | 0.68% |
26,180
-4,993
| -16% | -$154K |
|
|
ADVM
60
DELISTED
Adverum Biotechnologies
ADVM
| $763K | 0.67% |
+14,395
| New | +$866K |
|
61
Enanta Pharmaceuticals
ENTA
$372M
| $762K | 0.67% |
6,577
-9,036
| -58% | -$902K |
|
62
Rhythm Pharmaceuticals
RYTM
$7B
| $762K | 0.67% |
+24,374
| New | +$666K |
|
63
Gilead Sciences
GILD
$161B
| $761K | 0.67% |
10,744
-1,802
| -14% | -$127K |
|
64
Vanda Pharmaceuticals
VNDA
$312M
| $760K | 0.67% |
39,895
-24,145
| -38% | -$404K |
|
|
ARRY
65
DELISTED
Array Biopharma Inc
ARRY
| $757K | 0.67% |
45,087
-23,676
| -34% | -$377K |
|
|
66
Madrigal Pharmaceuticals
MDGL
$12.6B
| $755K | 0.67% |
2,699
-6,930
| -72% | -$1.22M |
|
|
IMGN
67
DELISTED
Immunogen Inc
IMGN
| $753K | 0.67% |
77,365
-35,182
| -31% | -$371K |
|
|
ICPT
68
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $753K | 0.67% |
8,970
-5,711
| -39% | -$418K |
|
|
PRTK
69
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $752K | 0.66% |
73,770
+31,037
| +73% | +$351K |
|
70
Ironwood Pharmaceuticals
IRWD
$611M
| $751K | 0.66% |
46,913
-23,550
| -33% | -$349K |
|
71
Fate Therapeutics
FATE
$281M
| $749K | 0.66% |
+66,073
| New | +$728K |
|
72
Alnylam Pharmaceuticals
ALNY
$36.3B
| $747K | 0.66% |
7,581
+1,529
| +25% | +$152K |
|
|
73
MediciNova
MNOV
$65M
| $746K | 0.66% |
+93,768
| New | +$969K |
|
74
MacroGenics
MGNX
$235M
| $745K | 0.66% |
36,070
-3,184
| -8% | -$71.7K |
|
75
Rocket Pharmaceuticals
RCKT
$348M
| $741K | 0.66% |
+37,750
| New | +$714K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2018 Portfolio in Review
As of Q2 2018, Virtus ETF Advisers held 280 positions worth $113M, down 1.9% from $115M the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Virtus ETF Advisers withdrew a net $5.51M in Q2 2018, closing 19 positions and reducing 100 holdings. Its most notable exit was Jounce Therapeutics, Inc. Common Stock, an estimated $1.32M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 79% a quarter earlier, followed by Financials and Technology.
Against the trend, Virtus ETF Advisers opened a new position in Fidelity MSCI Financials Index ETF worth $1.41M.
- Virtus ETF Advisers's largest Q2 2018 buy was Fidelity MSCI Financials Index ETF: 35,927 shares worth $1.41M.
- Virtus ETF Advisers added most to iShares 20+ Year Treasury Bond ETF in Q2 2018, an estimated $1.13M increase.
- Virtus ETF Advisers's biggest Q2 2018 reduction was Fidelity MSCI Information Technology Index ETF, cutting an estimated $2.78M.
- Virtus ETF Advisers fully exited Jounce Therapeutics, Inc. Common Stock in Q2 2018, selling an estimated $1.32M.
- Virtus ETF Advisers's ten largest holdings make up 14% of its $113M portfolio in Q2 2018.
- Virtus ETF Advisers opened 34 new positions and closed 19 in Q2 2018.
- Virtus ETF Advisers's portfolio value fell 1.9% quarter-over-quarter to $113M.
Based on Virtus ETF Advisers's 13F filing for Q2 2018, filed 10 Aug 2018.